LABT · Lakewood-Amedex Biotherapeutics Inc.
$0.58
+0.00 (+0.42%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has historically incurred recurring operating losses and negative operating cash flows and expects to continue to incur operating losses and consume cash as it executes its business plan. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed financial statements are issued. Because the Company will require additional financing within one year after the date these condensed financial statements are issued and such financing is not considered probable under the provisions of ASC 205-40, management has concluded that its plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.37M
Shares
2.37M
Volume · Oct 20
101.59K
Avg daily vol (3M)
2.44M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.58
Open$0.58
Day$0.57–0.62
Available close range$0.58–86.50
Avg vol 30d1.8M
Short int131K · 5.5% float · 1.0d
Short vol49%
DataApr 2026–Oct 2026
Filing10-Q · Aug 14
The closing range uses available history since Apr 23, 2026; less than a full year is stored.
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$7.35M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$4.58M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+104.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.5%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−66%
below
RSI (14)
22
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−71%
trailing
6-month return
−98%
trailing
Relative strength
−106%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
1 of 6 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.52% of float · ▲ +146.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
6 holders — 13F breadth
Squeeze score
57
elevated · 0–100
Fundamentals
EPS growth
+15%
Y/Y
Free cash flow
$-1.9M
Quant / Vol
risk profile
Volatility
210%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
26.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−66%
Bearish
RSI (14)
22
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
1 of 6 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.52% of float · ▲ +146.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
6 holders — 13F breadth
Price context
position in its available closing range
Range low $1
Now $1 · 0%
Range high $87
vs 50-day avg -66%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LABT
this stock
Lakewood-Amedex Biotherapeutics Inc.
|
$1.37M | — | — | — | 5.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.6% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
6
- % held
- 4.1%
- Reported
- 1 of 6
- Top holder
- Marex Group plc
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LABT | -16.8% | -71.0% | -98.4% | -39.6% | — |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -15.6% | -70.4% | -106.5% | -40.4% | — |